image
LeMaitre Vascular, Inc. LMAT
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
Watchlist
$ 81.92
2.05 %
$ 1.85 B
Market Cap
42.53
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LMAT stock under the worst case scenario is HIDDEN Compared to the current market price of 81.9 USD, LeMaitre Vascular, Inc. is HIDDEN

LMAT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LMAT stock under the base case scenario is HIDDEN Compared to the current market price of 81.9 USD, LeMaitre Vascular, Inc. is HIDDEN

LMAT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LMAT stock under the best case scenario is HIDDEN Compared to the current market price of 81.9 USD, LeMaitre Vascular, Inc. is HIDDEN

LMAT Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart LMAT

image
1M -5%
6M -24%
1Y 4%
3Y 88%
5Y 248%
All
$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
220 M REVENUE
13.63%
Growth Rates
1Year 13.63%
3Years 12.50%
5Years 13.40%
7Years 11.77%
10Years 11.95%
52.3 M OPERATING INCOME
42.34%
Growth Rates
1Year 42.34%
3Years 26.93%
5Years 27.08%
7Years 13.83%
10Years 23.48%
44 M NET INCOME
46.28%
Growth Rates
1Year 46.28%
3Years 17.85%
5Years 19.68%
7Years 14.40%
10Years 27.38%
44.1 M OPERATING CASH FLOW
20.06%
Growth Rates
1Year 20.06%
3Years 7.92%
5Years 25.49%
7Years 9.84%
10Years 23.12%
-200 M INVESTING CASH FLOW
-709.71%
Growth Rates
1Year -709.71%
3Years -48.53%
5Years -52.71%
7Years -31.80%
10Years -38.42%
158 M FINANCING CASH FLOW
2317.11%
Growth Rates
1Year 2317.11%
3Years 125.97%
5Years 105.00%
7Years 195.69%
10Years 37.26%
59.9 M REVENUE
7.46%
Growth Rates
1Year 13.63%
3Years 12.50%
5Years 13.40%
7Years 11.77%
10Years 11.95%
12.6 M OPERATING INCOME
-1.77%
Growth Rates
1Year 42.34%
3Years 26.93%
5Years 27.08%
7Years 13.83%
10Years 23.48%
11.2 M NET INCOME
0.39%
Growth Rates
1Year 46.28%
3Years 17.85%
5Years 19.68%
7Years 14.40%
10Years 27.38%
15.2 M OPERATING CASH FLOW
6.57%
Growth Rates
1Year 20.06%
3Years 7.92%
5Years 25.49%
7Years 9.84%
10Years 23.12%
-174 M INVESTING CASH FLOW
-1251.77%
Growth Rates
1Year -709.71%
3Years -48.53%
5Years -52.71%
7Years -31.80%
10Years -38.42%
164 M FINANCING CASH FLOW
5312.23%
Growth Rates
1Year 2317.11%
3Years 125.97%
5Years 105.00%
7Years 195.69%
10Years 37.26%
Balance Sheet LeMaitre Vascular, Inc.
image
Current Assets 402 M
Cash & Short-Term Investments 300 M
Receivables 30.1 M
Other Current Assets 72.4 M
Non-Current Assets 150 M
Long-Term Investments 0
PP&E 41.6 M
Other Non-Current Assets 108 M
54.32 %5.45 %13.12 %7.53 %19.58 %Total Assets$551.8m
Current Liabilities 30.6 M
Accounts Payable 1.76 M
Short-Term Debt 0
Other Current Liabilities 28.8 M
Non-Current Liabilities 184 M
Long-Term Debt 168 M
Other Non-Current Liabilities 16.1 M
13.45 %78.21 %7.53 %Total Liabilities$214.5m
EFFICIENCY
Earnings Waterfall LeMaitre Vascular, Inc.
image
Revenue 220 M
Cost Of Revenue 69 M
Gross Profit 151 M
Operating Expenses 98.6 M
Operating Income 52.3 M
Other Expenses 8.22 M
Net Income 44 M
250m250m200m200m150m150m100m100m50m50m00220m(69m)151m(99m)52m(8m)44mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.63% GROSS MARGIN
68.63%
Averages
1Year 68.63%
3Years 66.40%
5Years 66.05%
7Years 66.91%
10Years 67.82%
23.77% OPERATING MARGIN
23.77%
Averages
1Year 23.77%
3Years 18.61%
5Years 17.54%
7Years 18.27%
10Years 18.18%
20.03% NET MARGIN
20.03%
Averages
1Year 20.03%
3Years 16.12%
5Years 16.44%
7Years 17.03%
10Years 15.80%
13.06% ROE
13.06%
Averages
1Year 13.06%
3Years 10.29%
5Years 10.75%
7Years 11.92%
10Years 12.12%
7.98% ROA
7.98%
Averages
1Year 7.98%
3Years 7.77%
5Years 8.18%
7Years 9.34%
10Years 9.79%
7.76% ROIC
7.76%
Averages
1Year 7.76%
3Years 7.34%
5Years 7.18%
7Years 8.65%
10Years 9.71%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis LeMaitre Vascular, Inc.
image
40m40m35m35m30m30m25m25m20m20m15m15m10m10m5m5m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 44 M
Depreciation & Amortization 9.67 M
Capital Expenditures -6.96 M
Stock-Based Compensation 6.57 M
Change in Working Capital -20.1 M
Others 2.07 M
Free Cash Flow 37.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets LeMaitre Vascular, Inc.
image
Wall Street analysts predict an average 1-year price target for LMAT of $102 , with forecasts ranging from a low of $96 to a high of $110 .
LMAT Lowest Price Target Wall Street Target
96 USD 17.19%
LMAT Average Price Target Wall Street Target
102 USD 24.51%
LMAT Highest Price Target Wall Street Target
110 USD 34.28%
Price
Max Price Target
Min Price Target
Average Price Target
11011010510510010095959090858580807575Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.24% DIVIDEND YIELD
0.2 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.7000.7000.6000.6000.5000.5000.4000.4000.3000.3000.2000.2000.1000.1000.0000.0000.040.0450.0550.070.0850.0950.110.1250.140.160.20.040.0450.0550.070.0850.0950.110.1250.140.160.20.040.0450.0550.070.0850.0950.110.1250.140.160.040.160.0450.180.0550.220.070.280.0850.340.0950.380.110.440.1250.500.140.560.160.640.402015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership LeMaitre Vascular, Inc.
image
Sold
0-3 MONTHS
814 K USD 2
3-6 MONTHS
20.5 K USD 1
6-9 MONTHS
532 K USD 2
9-12 MONTHS
12.3 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV. globenewswire.com - 2 weeks ago
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript seekingalpha.com - 2 weeks ago
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago. zacks.com - 2 weeks ago
LeMaitre Q1 2025 Financial Results BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. globenewswire.com - 2 weeks ago
The Elephant In The Room - March Dividend Income Report I've sold some higher-yielding stocks and reduced my portfolio yield in March. The goal was to get closer to my core strategy of investing only in companies with low dividend yields, but high dividend growth potential. While my portfolio yield decreased from 4% to 3.5%, my 5-year CAGR dividend growth rate went from 8% to 11%. Despite much uncertainty, the Canadian stock market has remained relatively strong since the beginning of the year. seekingalpha.com - 4 weeks ago
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock? LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 1 month ago
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025 BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. globenewswire.com - 1 month ago
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility. zacks.com - 1 month ago
Small-Cap Dividend Stocks: Hidden Gems Or High-Risk Plays? - Top U.S. And Canadian Ones Over the past decade, the iShares S&P/TSX SmallCap Index ETF has underperformed broader markets due to its heavy exposure to resource-heavy sectors like energy and materials. Acme's dividend track record spans over 15 years, with a modest but steady payout. Debt levels remain low, and management is highly focused on operational efficiency. With regulated pricing, recurring revenue, and defensive characteristics, York Water is a favorite for income-seekers looking for small-cap stability. seekingalpha.com - 1 month ago
LeMaitre to Present at the 24th Annual Needham Virtual Healthcare Conference BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT. globenewswire.com - 1 month ago
Stocks Falling On Earnings - What To Do? February Dividend Income Report Alimentation Couche-Tard has several growth vectors in place with a clear 5-year plan, including organic growth and growth by acquisition. Starting in March, I will increase my Smith Manoeuvre contribution from $500 to $750 monthly. CCL Industries reported another good quarter with revenue up 9% and EPS up 5%. seekingalpha.com - 1 month ago
3 Reasons Growth Investors Will Love LeMaitre (LMAT) LeMaitre (LMAT) could produce exceptional returns because of its solid growth attributes. zacks.com - 1 month ago
8. Profile Summary

LeMaitre Vascular, Inc. LMAT

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.85 B
Dividend Yield 0.24%
Description LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Contact 63 Second Avenue, Burlington, MA, 01803 https://www.lemaitre.com
IPO Date Oct. 19, 2006
Employees 651
Officers Mr. George W. LeMaitre Chairman & Chief Executive Officer Mr. Trent G. Kamke Senior Vice President of Operations Dr. George D. LeMaitre FACS, M.D. Founder and Chairman of Scientific Advisory Board Mr. Dorian LeBlanc CPA Chief Financial Officer Ms. Kimberly L. Cieslak Vice President of Marketing Mr. Daniel J. Mumford Senior Director of Human Resources Mr. David B. Roberts President & Director Mr. Jonathan W. Ngau Senior Vice President of Information Technology Mr. Maik D. Helmers Senior Vice President of Sales – Central Europe Mr. Ryan H. Connelly Senior Vice President of Advanced Manufacturing Engineering